ES
MARKETS / NASDAQ / NRC
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · MID CAP

NRC Health NRC

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$137.4M
▼ 4.0% vs FY2024
Dividend streak
1 yrs
Raised every year since 2025
EPS · FY25
$50.00
Dividend / sh · FY25
$0.52
Payout · FY25
95%
ROE · FY25
51.2%
Net margin · FY25
8.4%
Dividend coverage
96.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 137.4M
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.040.080.120.160.10.02009201220152018202120242025
0.040.080.120.160.10.02016201920222025

8 cents of every revenue dollar became profit this year.

Per share
USD 50.00
Diluted EPS, FY2025
EPS Dividend
2040600.5250.002009201220152018202120242025
2040600.5250.002016201920222025

Earnings covered the dividend 96.2 times — the rest stayed in the company.

Profitability
51.2%
Return on equity, FY2025
ROE
408012016051.2%2009201220152018202120242025
408012016051.2%2016201920222025
Operating margin16.4%
Net margin8.4%
Return on assets8.7%

Each USD of equity produced 51 cents of profit this year.

Returned to shareholders
USD 31.0M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 11.0M
Net buybacksUSD 20.0M
Share of profit267.5%
Consecutive raises1 years

USD 11.0M in dividends and USD 20.0M in buybacks — 267% of the year's profit, so the payout drew on cash built up earlier.

Growth
+0.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−3.2%
+0.6%
+3.0%
+5.3%
Net income
−28.5%
−20.8%
−4.1%
+0.0%
EPS, diluted
+240.2%
+103.0%
Dividend / share
−14.8%
+19.9%
Returned to shareholders
−13.9%
+24.2%
+10.2%
+12.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.02B
Shares outstanding, FY2025
0.010.022009201220152018202120242025
0.020.022016201920222025
Change, 5 years−10.8%
Change, 10 years—

The share count shrank 11% in five years — the same company, cut into fewer, larger slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 134.9M
total assets, end of FY2025
Total assetsUSD 134.9M
EquityUSD 14.0M
CashUSD 4.1M
Gross debtUSD 75.0M
Net debtUSD 70.9M
Current ratio0.55×

Net debt stands at 507% of equity.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
50.00
1.04
1.25
1.27
1.46
1.45
1.26
·
·
·
·
·
·
2.17
1.69
1.26
1.26
Dividend / sh $
0.52
0.48
1.48
0.84
0.48
0.21
0.78
·
·
·
·
·
·
2.54
0.88
0.76
0.64
Payout %
95
46
117
66
24
28
97
56
74
139
57
·
14
115
51
44
50
ROE %
51.2
61.8
51.2
40.4
50.1
76.7
124.7
55.1
26.5
26.1
21.7
22.8
24.1
26.8
22.2
24.9
19.2
Shares out B
0.02
0.02
0.02
0.02
0.03
0.03
0.02
0.02
0.02
·
·
·
·
0.01
0.01
0.01
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
42 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 1 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed